<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>According to the update of the Finnish guidelines for management of patients with <z:hpo ids='HP_0005110'>atrial fibrillation</z:hpo> (AF) <z:chebi fb="0" ids="50659">dronedarone</z:chebi> should be used only in patients with non-permanent AF as a second line medication </plain></SENT>
<SENT sid="1" pm="."><plain>It is recommended to monitor the patients regularly and stop <z:chebi fb="0" ids="50659">dronedarone</z:chebi> if permanent AF, <z:hpo ids='HP_0001635'>heart failure</z:hpo> or other adverse events are detected </plain></SENT>
<SENT sid="2" pm="."><plain>Dabigatran and rivaroxaban can be used as an alternative to <z:chebi fb="8" ids="10033">warfarin</z:chebi> in patients requiring oral anticoagulation therapy </plain></SENT>
<SENT sid="3" pm="."><plain>The selection between <z:chebi fb="8" ids="10033">warfarin</z:chebi> and the new <z:chebi fb="2" ids="50249">anticoagulants</z:chebi> should be based on careful evaluation of the benefits and disadvantages of the drugs in a given patient </plain></SENT>
</text></document>